- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Rajesh Rajpal on the Future of Eye Lens Technology, Cataract Surgery
Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, addresses ongoing and future innovations in eye lens technology and instruments for cataract surgery.
Innovations in eye lens technology will continue to focus on improving patient’s functioning, with further progress being made in optimizing the cataract surgery process, said Raj Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson (J&J) Vision.
Transcript
Where do you see eye lens technology going in the next 5 to 10 years?
Certainly continuing to develop technology that continues to improve patient's functioning. We are hoping to continue to be able to provide options that patients can then choose, to minimize their need for glasses after cataract surgery.
We are also continuing to develop the instruments and the technology that's used in cataract surgery. We introduced at J&J Vision this year the VERITAS system, which is the phacoemulsification, or ultrasound system, that actually breaks apart the cataract during surgery.
So, as I was mentioning earlier, during cataract surgery, we make this microscopic incision, and then we use this phacoemulsification equipment, such as VERITAS, to break apart the hard lens. Just like in kidney stones, ultrasound is used to break apart the kidney stone. Then after we've removed all of the cataract, that's when we put the lens implant in place.
As I mentioned earlier, we also have developed and are continuing to develop advances in laser technology that also assist in that cataract surgery process in the operating room.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
